HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up - 15/01/16
Doi : 10.1016/j.jaad.2015.08.055
Marina Talamonti, MD a, ⁎ 
, Marco Galluzzo, MD a, Sergio Chimenti, MD a, Antonio Costanzo, MD b
, Marco Galluzzo, MD a, Sergio Chimenti, MD a, Antonio Costanzo, MD b a Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
b Dermatology Unit, Neurosciences, Mental Health, and Sensory Organs Department, Sapienza University of Rome, Rome, Italy
∗Correspondence to: Marina Talamonti, MD, Department of Dermatology, University of Rome “Tor Vergata,” Viale Oxford 81, 00133 Rome, Italy.
| The first two authors contributed equally to this work. |
|
| Funding sources: None. |
|
| Disclosure: Dr Chimenti served as a speaker for Pfizer, Abbvie, and MSD. Dr Costanzo served as a speaker for Pfizer and Abbvie. Drs Talamonti and Galluzzo have no conflicts of interest to declare. |
© 2015
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 74 - N° 2
P. 374-375 - février 2016 Retour au numéro
Article précédent
- A systematic review of pulse steroid therapy for alopecia areata
- Rony Shreberk-Hassidim, Yuval Ramot, Zvi Gilula, Abraham Zlotogorski
- Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled trial
- Amy E. Gilliam, Nanette Madden, Mya Sendowski, Margaret Mioduszewski, Karen G. Duderstadt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?